Skip to content
Open in App
GSK BDR logo

GSK BDR

web2

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture...

Symbol · G1SK34
Company profile

About

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Neladalkib FDA target decision

KEY STEP

The FDA target decision date for neladalkib is November 27, 2026. This is the next near term regulatory test for a lead lung cancer asset acquired with Nuvalent.

Roadmap reference

Expanded phase III trial starts in 2026

KEY STEP

GSK expects more than 20 phase III trial starts in 2026, up from its previous target of 10, as part of its accelerated late stage development program.

Roadmap reference
People

Company team

VS

Vishal Sikka

Independent Non-Executive Director

Company leadership profile.

WM

Wendy Mira Becker

Independent Non-Executive Director

Company leadership profile.

JR

Jonathan Richard Symonds

Chair

Company leadership profile.

LV

Luke Victor Miels

CEO & Director

Company leadership profile.

JB

Julie Belita Brown

CFO & Executive Director

Company leadership profile.

CA

Charles A. Bancroft

Senior Independent Non-Executive Director

Company leadership profile.

HV

Harold V. Barron

Non-Executive Director

Company leadership profile.

AC

Anne C. Beal

Independent Non-Executive Director

Company leadership profile.

HC

Harry C. Dietz

Independent Non-Executive Director

Company leadership profile.

EM

Elizabeth McKee Anderson

Independent Non-Executive Director

Company leadership profile.

TL

Tsun-Huei Lee

Independent Non-Executive Director

Company leadership profile.

GR

Gavin Robert Screaton

Independent Non-Executive Director

Company leadership profile.

RW

Roy Willem Odilia Jakobs

Independent Non-Executive Director

Company leadership profile.

Expert coverage

1 expert evaluated GSK BDR.

Orbitrum research

Experts evaluating GSK BDR

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment